ATE325533T1 - Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen - Google Patents

Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen

Info

Publication number
ATE325533T1
ATE325533T1 AT96933209T AT96933209T ATE325533T1 AT E325533 T1 ATE325533 T1 AT E325533T1 AT 96933209 T AT96933209 T AT 96933209T AT 96933209 T AT96933209 T AT 96933209T AT E325533 T1 ATE325533 T1 AT E325533T1
Authority
AT
Austria
Prior art keywords
cells
virus
fibronectin
hematopoietic
mediated dna
Prior art date
Application number
AT96933209T
Other languages
German (de)
English (en)
Inventor
David A Williams
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/536,891 external-priority patent/US6033907A/en
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Application granted granted Critical
Publication of ATE325533T1 publication Critical patent/ATE325533T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96933209T 1995-09-29 1996-09-30 Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen ATE325533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,891 US6033907A (en) 1995-09-29 1995-09-29 Enhanced virus-mediated DNA transfer
US2416996P 1996-08-19 1996-08-19

Publications (1)

Publication Number Publication Date
ATE325533T1 true ATE325533T1 (de) 2006-06-15

Family

ID=26698123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933209T ATE325533T1 (de) 1995-09-29 1996-09-30 Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen

Country Status (12)

Country Link
US (3) US6670177B2 (cg-RX-API-DMAC7.html)
EP (2) EP1686181A3 (cg-RX-API-DMAC7.html)
JP (3) JP4365456B2 (cg-RX-API-DMAC7.html)
KR (2) KR100506569B1 (cg-RX-API-DMAC7.html)
CN (1) CN1326999C (cg-RX-API-DMAC7.html)
AT (1) ATE325533T1 (cg-RX-API-DMAC7.html)
AU (1) AU720359B2 (cg-RX-API-DMAC7.html)
CA (1) CA2233316C (cg-RX-API-DMAC7.html)
DE (1) DE69636124T2 (cg-RX-API-DMAC7.html)
ES (1) ES2265153T3 (cg-RX-API-DMAC7.html)
TW (1) TW520395B (cg-RX-API-DMAC7.html)
WO (1) WO1997011604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) * 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
CA2233316C (en) * 1995-09-29 2010-12-14 Indiana University Foundation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
DE69722176T2 (de) * 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
ATE414780T1 (de) 1998-07-01 2008-12-15 Takara Bio Inc Methoden für gentransfer mit retroviren
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
WO2001004332A1 (en) * 1999-07-08 2001-01-18 Burkhard Hennemann Method to improve viral infection
US7910368B2 (en) * 2001-08-15 2011-03-22 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic lymphocytes
DE60335253D1 (de) 2002-03-25 2011-01-20 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
DE10325173B4 (de) * 2003-06-04 2007-11-08 Stief, Thomas, Dr.med. Nachweisverfahren für Fibrinogen und/oder Fibrinogen-Derivate
DE602004025591D1 (de) 2003-08-22 2010-04-01 Takara Bio Inc Verfahren zur herstellung zytotoxischer lymphozyten
JPWO2005073385A1 (ja) * 2004-01-29 2008-01-10 独立行政法人産業技術総合研究所 遺伝子導入効率を上昇させるための組成物および方法
US20060190184A1 (en) * 2005-02-23 2006-08-24 Incogen, Inc. System and method using a visual or audio-visual programming environment to enable and optimize systems-level research in life sciences
EP1916302A4 (en) 2005-08-17 2009-10-21 Takara Bio Inc PROCESS FOR THE PRODUCTION OF LYMPHOCYTES
EP2462952A1 (en) 2010-12-10 2012-06-13 Medizinische Universität Graz Cancer gene therapy using nucleic acids encoding US28
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
CN108220246B (zh) * 2011-09-30 2022-07-12 蓝鸟生物公司 用于改善病毒转导的化合物
WO2017068419A2 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
JP6970106B2 (ja) 2016-02-12 2021-11-24 ブルーバード バイオ， インコーポレイテッド Ｖｃｎエンハンサー組成物およびその使用方法
US11352605B2 (en) 2016-05-12 2022-06-07 Erasmus University Medical Center Rotterdam Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
EP3492592B1 (en) * 2016-07-29 2024-11-06 Takara Bio Inc. Fibronectin fragment to be used for stem cell production
WO2018053463A1 (en) 2016-09-19 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
CN110862917B (zh) * 2019-11-18 2020-08-25 中国人民解放军军事科学院军事医学研究院 细胞单集落挑选装置及制备方法和应用
US12180444B2 (en) 2019-12-30 2024-12-31 Saint-Gobain Performance Plastics Corporation Containers and methods for cell transduction
WO2022165216A1 (en) * 2021-01-29 2022-08-04 Carpenter Margaret Clark Methods for increasing viral transduction of cells
KR20250131773A (ko) * 2022-11-18 2025-09-03 생-고뱅 퍼포먼스 플라스틱스 코포레이션 세포 형질도입을 위한 앱타머, 용기 및 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT385658B (de) * 1985-03-28 1988-05-10 Serotherapeutisches Inst Wien Verfahren zur herstellung einer fuer die anwendung beim menschen geeigneten fibronektinloesung
US4980279A (en) * 1986-04-15 1990-12-25 Scripps Clinic And Research Foundation Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
US4839464A (en) * 1987-08-25 1989-06-13 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5019646A (en) * 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5116368A (en) * 1987-08-25 1992-05-26 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
JP2561131B2 (ja) 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
JPH04505261A (ja) 1989-05-10 1992-09-17 スローン―ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ ポルｉｉｉプロモーターの制御下の転写可能な外来ｄｎａを含む安定的に形質転換された真核細胞
SE8901687D0 (sv) * 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
JP2561149B2 (ja) 1989-05-26 1996-12-04 寳酒造株式会社 機能性ポリペプチド
US5198423A (en) * 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5492890A (en) * 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
US5834589A (en) * 1990-12-14 1998-11-10 New York University Chimeric viral receptor polypeptides
US5470726A (en) * 1991-02-22 1995-11-28 Fred Hutchinson Cancer Research Center Retrovirus packaging and producer cell lines based on gibbon ape leukemia virus
WO1992018615A1 (en) * 1991-04-09 1992-10-29 Indiana University Foundation System and process for supporting hematopoietic cells
EP0631618A4 (en) * 1992-03-04 1995-09-27 Systemix Inc CULTIVATION OF HEMOPOETIC STEM CELLS AND THEIR GENETOLOGICAL PRODUCTION.
US5401836A (en) 1992-07-16 1995-03-28 Pioneer Hi-Bre International, Inc. Brassica regulatory sequence for root-specific or root-abundant gene expression
US5229172A (en) * 1993-01-19 1993-07-20 Medtronic, Inc. Modification of polymeric surface by graft polymerization
US5299172A (en) * 1993-02-03 1994-03-29 Halliburton Geophysical Services, Inc. Method for adjusting crystal hydrophone output
US6051427A (en) * 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5811274A (en) * 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
CA2233316C (en) * 1995-09-29 2010-12-14 Indiana University Foundation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
ATE325884T1 (de) * 1995-11-13 2006-06-15 Takara Bio Inc Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren

Also Published As

Publication number Publication date
EP0873049A1 (en) 1998-10-28
CA2233316A1 (en) 1997-04-03
DE69636124T2 (de) 2006-12-21
US20090092589A1 (en) 2009-04-09
US8889419B2 (en) 2014-11-18
KR19990063945A (ko) 1999-07-26
JP2004267214A (ja) 2004-09-30
US20040265284A1 (en) 2004-12-30
KR100793625B1 (ko) 2008-01-11
US20030039640A1 (en) 2003-02-27
EP0873049A4 (cg-RX-API-DMAC7.html) 1998-12-02
ES2265153T3 (es) 2007-02-01
AU7203396A (en) 1997-04-17
WO1997011604A1 (en) 1997-04-03
JP2009261407A (ja) 2009-11-12
CA2233316C (en) 2010-12-14
EP1686181A2 (en) 2006-08-02
CN1202799A (zh) 1998-12-23
US6670177B2 (en) 2003-12-30
JP3940732B2 (ja) 2007-07-04
CN1326999C (zh) 2007-07-18
EP1686181A3 (en) 2006-08-09
DE69636124D1 (de) 2006-06-14
EP0873049B1 (en) 2006-05-10
AU720359B2 (en) 2000-06-01
JP2000507084A (ja) 2000-06-13
KR100506569B1 (ko) 2005-12-26
JP4365456B2 (ja) 2009-11-18
KR20050046016A (ko) 2005-05-17
TW520395B (en) 2003-02-11

Similar Documents

Publication Publication Date Title
ATE325533T1 (de) Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
ATE370229T1 (de) Ein verstärkter, durch viren vermittelter dna- transfer
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
DE69638314D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
DK0864645T3 (da) Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DE69736006D1 (de) Verbesserungen des stärkegehaltes von pflanzen
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
ATE542891T1 (de) Verfahren zur herstellung von biologischen produkten in protein-freier kultur
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
ATE414162T1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE205253T1 (de) Induzierbare virusresistenz bei pflanzen
ATE299931T1 (de) Kaliumkanal-proteine zur verwendung in gentherapie zur verminderung von erektiler dysfunktion
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
ATE301721T1 (de) In vivo herstellung von replicativen molekülen
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
DE59902472D1 (de) Zusammensetzung zur induktion einer tumorspezifischen immunantwort, verfahren zu deren herstellung sowie verwendung der zusammensetzung zur behandlung von neoplasien
BRPI0002694C1 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
MX9802766A (es) Vacuna contra la influenza.
ES2175184T3 (es) Virus que expresan proteinas toxicas y leneas celulares productoras.
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen
FI881294A0 (fi) FSME-viruksen läntisen alatyypin eristettyjä DNA- ja RNA-molekyylejä, näitä sisältäviä vektoreita ja soluviljelmiä sekä menetelmä näiden koodittamien peptidien valmistamiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties